<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="for veterinary use (RVFV, bluetongue [34], African horsesickness [35], canine" exact="influenza" post="[36], and for human use [influenza [37] (US and"/>
 <result pre="It is relevant to note that FDA labeling of live" exact="influenza" post="vaccine (FluMist®), containing four genetically engineered influenza strains, does"/>
 <result pre="labeling of live influenza vaccine (FluMist®), containing four genetically engineered" exact="influenza" post="strains, does not contain precautions for reassortment. Table 2"/>
 <result pre="vaccine-associated paralytic polio caused by circulating recombinant strains Bovine viral" exact="diarrhea" post="Cows Pestivirus positive sense non-segmented ssRNA Recombination of LAV"/>
 <result pre="to virulent strain causing mucosal disease Sporadic mucosal disease Infectious" exact="laryngotracheitis" post="virus Chickens Herpesvirus double stranded linear DNA Recombination of"/>
 <result pre="reversion and reassortment. The benefit:risk ratio (cases of RVF illness," exact="retinitis" post="or death prevented per excess illness caused by a"/>
 <result pre="36Rodriguez L, Nogales A, Reilly EC, et al. A live-attenuated" exact="influenza" post="vaccine for H3N2 canine influenza virus. 2017; 504: 96–106."/>
 <result pre="EC, et al. A live-attenuated influenza vaccine for H3N2 canine" exact="influenza" post="virus. 2017; 504: 96–106. 37RodriguezL.Blanco-LoboP.ReillyE.C.Comparative Study of the Temperature"/>
</results>
